COVID-19住院患者出院后3、6、9、12个月呼吸结局的前瞻性研究
这项前瞻性纵向队列研究纳入83例无需机械通气的重症COVID-19住院患者,在出院后3、6、9、12个月随访呼吸功能。多数患者肺生理和运动能力随时间改善,但部分患者12个月时仍存在DLCO受损和影像学异常。女性与DLCO受损风险升高相关,住院期间HRCT肺炎峰值评分与影像学异常相关。
要点
- 重症COVID-19康复者多数呼吸功能随时间改善,但部分12个月时仍有生理和影像异常。
核心结论
- 多数重症COVID-19康复者呼吸困难评分和运动能力随时间改善,但部分患者12个月时仍有持续生理和影像学改变。
研究设计与样本
- 前瞻性纵向队列研究,纳入2020年2月1日至3月31日武汉大学人民医院83例无需机械通气的重症COVID-19住院患者,出院后3、6、9、12个月随访。
主要发现
- 研究期间DLCO显著降低,中位值3个月为预计值77%(IQR 67-87),6个月为76%(68-90),12个月为88%(78-101)。
- 出院12个月时,20例(24%)患者影像学改变持续存在。
临床怎么用
- 对重症COVID-19康复者应进行呼吸随访,关注DLCO和胸部影像学变化。
- 女性和住院期间HRCT肺炎评分较高的患者可能需更密切的呼吸功能监测。
局限性
- 研究排除有高血压、糖尿病、心血管疾病、癌症、慢性肺病(包括哮喘或COPD)或吸烟史的患者,以及需要插管机械通气的患者。
- 135例符合条件患者中仅83例(61%)参与研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The consequences of COVID-19 in those who recover from acute infection requiring hospitalisation have yet to be clearly defined. We aimed to describe the temporal trends in respiratory outcomes over 12 months in patients hospitalised for severe COVID-19 and to investigate the associated risk factors. METHODS: In this prospective, longitudinal, cohort study, patients admitted to hospital for severe COVID-19 who did not require mechanical ventilation were prospectively followed up at 3 months, 6 months, 9 months, and 12 months after discharge from Renmin Hospital of Wuhan University, Wuhan, China. Patients with a history of hypertension; diabetes; cardiovascular disease; cancer; and chronic lung disease, including asthma or chronic obstructive pulmonary disease; or a history of smoking documented at time of hospital admission were excluded at time of electronic case-note review. Patients who required intubation and mechanical ventilation were excluded given the potential for the consequences of mechanical ventilation itself to influence the factors under investigation. During the follow-up visits, patients were interviewed and underwent physical examination, routine blood test, pulmonary function tests (ie, diffusing capacity of the lungs for carbon monoxide [DLCO]; forced expiratory flow between 25% and 75% of forced vital capacity [FVC]; functional residual capacity; FVC; FEV1; residual volume; total lung capacity; and vital capacity), chest high-resolution CT (HRCT), and 6-min walk distance test, as well as assessment using a modified Medical Research Council dyspnoea scale (mMRC). FINDINGS: Between Feb 1, and March 31, 2020, of 135 eligible patients, 83 (61%) patients participated in this study. The median age of participants was 60 years (IQR 52-66). Temporal improvement in pulmonary physiology and exercise capacity was observed in most patients; however, persistent physiological and radiographic abnormalities remained in some patients with COVID-19 at 12 months after discharge. We found a significant reduction in DLCO over the study period, with a median of 77% of predicted (IQR 67-87) at 3 months, 76% of predicted (68-90) at 6 months, and 88% of predicted (78-101) at 12 months after discharge. At 12 months after discharge, radiological changes persisted in 20 (24%) patients. Multivariate logistic regression showed increasing odds of impaired DLCO associated with female sex (odds ratio 8·61 [95% CI 2·83-26·2; p=0·0002) and radiological abnormalities were associated with peak HRCT pneumonia scores during hospitalisation (1·36 [1·13-1·62]; p=0·0009). INTERPRETATION: In most patients who recovered from severe COVID-19, dyspnoea scores and exercise capacity improved over time; however, in a subgroup of patients at 12 months we found evidence of persistent physiological and radiographic change. A unified pathway for the respiratory follow-up of patients with COVID-19 is required. FUNDING: National Natural Science Foundation of China, UK Medical Research Council, and National Institute for Health Research Southampton Biomedical Research Centre. TRANSLATION: For the Chinese translation of the abstract see Supplementary Materials section.
引用
- Wu X, Liu X, Zhou Y, et al. 3-month, 6-month, 9-month, and 12-month respiratory outcomes in patients following COVID-19-related hospitalisation: a prospective study. Lancet Respir Med. 2021. PMID: 33964245. doi:10.1016/S2213-2600(21)00174-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。